Literature DB >> 8608519

Post-irradiation malignant mesothelioma.

A Cavazza1, L B Travis, W D Travis, J T Wolfe, M L Foo, D J Gillespie, N Weidner, T V Colby.   

Abstract

BACKGROUND: Approximately 30 patients with malignant mesothelioma following radiotherapy have been described. Population-based studies of this occurrence have not been reported.
METHODS: Patients with malignant mesothelioma of the pleura were collected. All of the patients had a prior cancer and had received radiotherapy to the region in which the malignant mesothelioma developed. Data from the National Cancer Institute's Surveillance, Epidemiology and End Results Program and the Connecticut Tumor Registry were evaluated for cases of malignant mesothelioma of the pleura occurring in patients with a previous cancer. The literature on post-irradiation malignant mesotheliomas was reviewed.
RESULTS: Eight patients (4 men, 4 women) with malignant mesothelioma occurring in sites of radiotherapy for a prior tumor were identified. The mean age at diagnosis of mesothelioma was 45 years (range: 22-78 years), and the average interval between radiotherapy and the mesothelioma was 21 years (range: 11-29 years). Three of the patients had also received chemotherapy. Histologically, the mesotheliomas were epithelial in five cases, biphasic in one, and sarcomatous in one. One hundred forty-two patients were identified in the epidemiologic survey. The majority were men (89%), with a mean age for all patients of 68.5 years (range: 35-86 years) and a median latency between first cancer and mesothelioma of 4.3 years (range: 2 months-29.9 years).
CONCLUSIONS: Mesotheliomas rarely develop as second malignant neoplasms. Within a large, population-based survey of patients with cancer, temporal patterns and demographic features of most second primary mesotheliomas were similar to asbestos-related tumors, although the late effects of cancer treatment might have contributed to the occurrence of cancer in some patients.

Entities:  

Mesh:

Year:  1996        PMID: 8608519     DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  Novel systemic therapy against malignant pleural mesothelioma.

Authors:  Michael R Mancuso; Joel W Neal
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Case report of delayed radiotherapy-related pleural effusion following chest radiotherapy for lymphoma.

Authors:  Panxiao Shen; Yunxiang Zeng; Weizhan Luo; Yingying Gu; Jinlin Wang
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 3.  Mesothelioma: cases associated with non-occupational and low dose exposures.

Authors:  G Hillerdal
Journal:  Occup Environ Med       Date:  1999-08       Impact factor: 4.402

4.  Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Authors:  Alain C Borczuk; Jianming Pei; Robert N Taub; Brynn Levy; Odelia Nahum; Jinli Chen; Katherine Chen; Joseph R Testa
Journal:  Cancer Biol Ther       Date:  2016-02-06       Impact factor: 4.742

Review 5.  Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"

Authors:  Vincenzo Di Noia; Emanuele Vita; Miriam Ferrara; Antonia Strippoli; Michele Basso; Giovanni Schinzari; Alessandra Cassano; Emilio Bria; Carlo Barone; Ettore D'Argento
Journal:  Curr Treat Options Oncol       Date:  2019-02-21

6.  Receptor role of the annexin A2 in the mesothelial endocytosis of crocidolite fibers.

Authors:  Kyoko Yamashita; Hirotaka Nagai; Shinya Toyokuni
Journal:  Lab Invest       Date:  2015-04-27       Impact factor: 5.662

Review 7.  Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.

Authors:  Shoshana J Weiner; Siyamek Neragi-Miandoab
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-12       Impact factor: 4.553

Review 8.  Mesothelioma epidemiology, carcinogenesis, and pathogenesis.

Authors:  Haining Yang; Joseph R Testa; Michele Carbone
Journal:  Curr Treat Options Oncol       Date:  2008-08-15

Review 9.  [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].

Authors:  Volker Neumann; Stefan Löseke; Andrea Tannapfel
Journal:  Med Klin (Munich)       Date:  2009-10-25

Review 10.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines.

Authors:  Giulio Rossi; Fabio Davoli; Venerino Poletti; Alberto Cavazza; Filippo Lococo
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.